Vysis LSI MYB (6q23) SpectrumAqua Probe
For more information, contact Abbott.
For more information, contact Abbott.
| PRODUCT NAME | UNIT SIZE | ORDER NUMBER | GTIN |
|---|
Vysis LSI MYB (6q23) SpectrumAqua DNA probe hybridizes to human chromosome 6q23. The hybridized probe fluoresces with moderate to bright intensity both in interphase nuclei and on metaphase chromosomes. In interphase nuclei of normal cells, the probe generally appears as two distinct signals. The probe may also appear as three or four signals, depending upon DNA condensation, and relative distance between chromatids. The signals may also appear as diffuse or split signals. In a normal metaphase, the probe may appear as one or two signals on each chromosome 6.
Hybridization of this probe to interphase and metaphase nuclei of normal cells is expected to be seen as two aqua signals. The anticipated signal pattern in individuals with a deletion of the 6q23 region would be seen as a single aqua signal. Other patterns may be observed if additional genetic alterations are present.
Hybridization of this probe to interphase and metaphase nuclei of normal cells is expected to be seen as two aqua signals. The anticipated signal pattern in individuals with a deletion of the 6q23 region would be seen as a single aqua signal. Other patterns may be observed if additional genetic alterations are present.
Normal Hybridization: Normal cell hybridization using the Vysis LSI MYB (6q23) Probe.
Abnormal Hybridization: Abnormal cell hybridization using the Vysis LSI MYB (6q23) Probe.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.